86 related articles for article (PubMed ID: 6308149)
21. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
22. Function of dopamine receptors in Parkinson's disease: prolactin responses.
Laihinen A; Rinne UK
Neurology; 1986 Mar; 36(3):393-5. PubMed ID: 3081830
[TBL] [Abstract][Full Text] [Related]
23. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Parkinson's disease: problems with a progressing disease.
Rinne UK
J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627
[TBL] [Abstract][Full Text] [Related]
25. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.
Fuxe K; Marcellino D; Genedani S; Agnati L
Mov Disord; 2007 Oct; 22(14):1990-2017. PubMed ID: 17618524
[TBL] [Abstract][Full Text] [Related]
26. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
27. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Chase TN; Oh JD
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
[TBL] [Abstract][Full Text] [Related]
28. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
29. Function of dopamine receptors in young-onset Parkinson's disease: prolactin response.
Kostic VS; Marinkovic Z; Filipovic S; Momcilovic D
Mov Disord; 1993 Apr; 8(2):227-9. PubMed ID: 8474497
[TBL] [Abstract][Full Text] [Related]
30. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
31. Chemical neurotransmission in the parkinsonian brain.
Rinne UK; Rinne JO; Rinne JK; Laakso K
Med Biol; 1987; 65(2-3):75-81. PubMed ID: 2821331
[TBL] [Abstract][Full Text] [Related]
32. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
33. [Dopaminergic receptors on lymphocytes in idiopathic Parkinson's disease (author's transl)].
Le Fur G; Meininger V; Baulac M; Phan T; Uzan A
Rev Neurol (Paris); 1981; 137(2):89-96. PubMed ID: 7244495
[TBL] [Abstract][Full Text] [Related]
34. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
Mouradian MM; Chase TN
Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152
[TBL] [Abstract][Full Text] [Related]
36. What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley MJ; Jenner P
Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
[TBL] [Abstract][Full Text] [Related]
37. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy.
Guttman M; Seeman P
Adv Neurol; 1987; 45():51-7. PubMed ID: 2950731
[No Abstract] [Full Text] [Related]
39. [Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
Marais C
Sem Hop; 1978 May; 54(13-16):563-7. PubMed ID: 211603
[TBL] [Abstract][Full Text] [Related]
40. Dopamine D-1 receptors in the parkinsonian brain.
Rinne JO; Rinne JK; Laakso K; Lönnberg P; Rinne UK
Brain Res; 1985 Dec; 359(1-2):306-10. PubMed ID: 2934111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
